JP-11646 (JP11646) is a novel potent, selective, non-ATP competitive Pim2 inhibitor with IC50 of 0.5/1/24 nM for Pim2/3/1, respectively.
JP-11646 shows less potency for other kinases in a kinase selectivity panel.
JP-11646 exhibits 4-760-fold greater suppression of MM proliferation and viability than ATP-competitive PIM inhibitors.
JP-11646 significant reduces tumor burden and increases median survival in xenogeneic myeloma murine models.
